Latest Breaking News On - Deric dube - Page 3 : vimarsana.com

Travere Therapeutics, Inc (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript

Operator: Good day and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference Call. Today s conference is being recorded.

United statesGreg harrisonJula inrigDeric dubeAnupam ramaLiisa baykoPeter heermaAnne crotteauJoseph schwartzWilliam blairTyler van burenTim lugoCarter gouldMaury raycroftChris clineTravere therapeutics inc

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval .

Deric dubeDrug administrationEuropean unionDevices agencyProgram updatesCommittee for medicinal products human useRenalys pharma incTravere therapeutics incExchange commissionContinuing operationsQuarter ended decemberNew drug applicationMedicinal productsHuman useConditional marketing authorizationRenalys pharma

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in JapanSAN DIEGO, Jan. 25, 2024 Travere.

South koreaRepublic ofDeric dubeCatalys pacificRenalys pharmaRenalys pharma incTravere therapeutics incDevices agencyExchange commissionMedical devices agencySoutheast asianTravere therapeuticsImportant safetyEndothelin receptor antagonistsUpper limitFetal toxicity

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic ofRenalys pharmaCatalys pacificDeric dubeExchange commissionTravere therapeutics incRenalys pharma incDevices agencyTherapeutics announces licensing agreementCommercialize sparsentanSoutheast asianMedical devices agencyTravere therapeuticsImportant safetyEndothelin receptor antagonists

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations

Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic ofDeric dubeRenalys pharmaCatalys pacificRenalys pharma incExchange commissionTravere therapeutics incDevices agencyMedical devices agencySoutheast asianTravere therapeuticsImportant safetyEndothelin receptor antagonistsUpper limitFetal toxicity